ZyVersa Therapeutics Inc.
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $15.02 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
ZyVersa Therapeutics Inc. had its IPO on 2022-12-12 under the ticker symbol ZVSA.
The company operates in the Healthcare sector and Biotechnology industry. ZyVersa Therapeutics Inc. has a staff strength of 6 employees.
Shares of ZyVersa Therapeutics Inc. opened at $1.62 at the start of the last trading session i.e. 2023-03-22.
The stocks traded within a range of $1.62 - $1.66, and closed at $1.63.
This is a 0% increase from the previous day's closing price.
A total volume of 5,622 shares were traded at the close of the day’s session.
In the last one week, shares of ZyVersa Therapeutics Inc. have slipped by -22.01%.
ZyVersa Therapeutics Inc.'s Key Ratios
ZyVersa Therapeutics Inc. has a market cap of $15.02 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months ZyVersa Therapeutics Inc.’s revenue was $0 with a gross profit of $0 and an EBITDA of $-10413101. The EBITDA ratio measures ZyVersa Therapeutics Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, ZyVersa Therapeutics Inc.’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q3, ZyVersa Therapeutics Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
ZyVersa Therapeutics Inc.’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into ZyVersa Therapeutics Inc.’s profitability.
ZyVersa Therapeutics Inc. stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
ZyVersa Therapeutics Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $79.40 million
- Total Liabilities
- $1.63 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
ZyVersa Therapeutics Inc. ended 2023 with $79.40 million in total assets and $0 in total liabilities. Its intangible assets were valued at $79.40 million while shareholder equity stood at $-4158937.00.
ZyVersa Therapeutics Inc. ended 2023 with $0 in deferred long-term liabilities, $1.63 million in other current liabilities, 78556033.00 in common stock, $-4159185.00 in retained earnings and $0 in goodwill. Its cash balance stood at $213564.00 and cash and short-term investments were $213564.00. The company’s total short-term debt was $0 while long-term debt stood at $0.
ZyVersa Therapeutics Inc.’s total current assets stands at $438564.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $6.50 million and inventory worth $0.
In 2023, ZyVersa Therapeutics Inc.'s operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, ZyVersa Therapeutics Inc. paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
ZyVersa Therapeutics Inc. stock is currently trading at $1.63 per share. It touched a 52-week high of $25 and a 52-week low of $25. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $2.19 and 200-day moving average was $0 The short ratio stood at 0.54 indicating a short percent outstanding of 0%.
Around 5510.6% of the company’s stock are held by insiders while 575.2% are held by institutions.
Frequently Asked Questions About ZyVersa Therapeutics Inc.
Similar Industry Stocks (Biotechnology)
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.